Nasdaq CopenhagenIFRS · DKK

LEO Pharma A/S

LEO Pharma A/S is a Denmark-based pharmaceutical company focused on dermatology and skin-health medicines. Its business includes researching, developing, manufacturing, and commercializing prescription treatments used by patients and healthcare professionals in multiple regions.

Kysy yhtiöstä
Liikevaihto13,5mrd DKK
+8,4 %v/v
Liikevoitto (EBIT)2 279milj. DKK
+299,4 %v/v
EBIT-marginaali16,9%
+26,1 %-yks.v/v
Nettotulos2 489milj. DKK
+240,1 %v/v
Vapaa kassavirta999milj. DKK
+16 550,0 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2021–2025

−5051015mrd DKK2021: 10,0 mrd DKK2021: EBIT −4,2 mrd DKK20212022: 10,6 mrd DKK2022: EBIT −3,3 mrd DKK20222023: 11,4 mrd DKK2023: EBIT −1,7 mrd DKK20232024: 12,5 mrd DKK2024: EBIT −1,1 mrd DKK20242025: 13,5 mrd DKK2025: EBIT 2,3 mrd DKK202513,52,3
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: LEO Pharma A/S

Liiketoiminta

Osuus liikevaihdosta
Dermatology medicines80 %

Prescription therapies for chronic and acute skin diseases, including branded medicines sold through healthcare channels.

In-licensed products15 %

Externally originated dermatology assets commercialized through licensing and partnership agreements.

Development pipeline5 %

Clinical-stage dermatology programs and related research activity that can become future products.

Asiakkaat

LEO Pharma sells primarily to healthcare providers and the pharmaceutical distribution channel rather than to end consumers directly. Its products are used by dermatologists, hospitals, clinics, and pharmacies that prescribe or dispense treatments for skin diseases. The company also depends on licensing and collaboration partners for selected programs and geographic reach.

Dermatology specialists

Dermatologists and specialist prescribers buy LEO Pharma medicines for skin diseases such as psoriasis and related conditions.

Hospitals and clinics

Hospital outpatient and specialty clinics use branded prescription treatments for patients needing physician-managed therapy.

Pharmacies and wholesalers

Distribution partners stock and supply the company's medicines to patients and healthcare providers.

License partners

Partners buy rights, co-commercialization options, or development access for selected dermatology assets.

Strategia

LEO Pharma's strategy centers on expanding its dermatology portfolio through development, licensing, and commercial partnerships. The report highlights in-licensed assets and collaborations that broaden the product base while preserving optionality in markets outside core territories.

Build the dermatology pipelineKeskipitkä aikaväli

A broader pipeline reduces reliance on a small number of branded products and supports longer-term growth.

Use licensing and partnershipsLyhyt aikaväli

External programs can extend the portfolio without requiring all rights to be developed in-house.

Strengthen international commercializationKeskipitkä aikaväli

Broader geographic reach increases the addressable market for specialized dermatology products.

Maantiede

LEO Pharma operates as an international pharmaceutical business headquartered in Denmark, with commercial and development activity spanning North America, Europe, and other regions. The report excerpt points to material exposure to the U.S. market and additional regions for approved dermatology products, which makes regulatory access and reimbursement important drivers of geographic performance.

Riskit

LEO Pharma faces typical pharmaceutical risks from clinical development uncertainty, regulatory approval, and market access for specialty medicines. Its dependence on dermatology assets and external partnerships also creates concentration and execution risk if development timelines slip or partnered programs do not progress as planned.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Regulatory and reimbursement pressure1Clinical development failure2Partner concentration3Manufacturing and supply disruption4
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Regulatory and reimbursement pressureVaikutus: KorkeaTodennäköisyys: Korkea

    Specialty medicines depend on approvals, label breadth, and payer coverage to reach patients.

    Kohdistuu: U.S. and other regulated markets

  2. Clinical development failureVaikutus: KorkeaTodennäköisyys: Kohtalainen

    New dermatology programs can fail to meet efficacy or safety expectations, delaying or preventing commercialization.

    Kohdistuu: Pipeline assets and partnered programs

  3. Partner concentrationVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    The company relies on licensing and collaboration structures for some assets and rights.

    Kohdistuu: In-licensed and co-commercialized programs

  4. Manufacturing and supply disruptionVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Pharmaceutical products require consistent quality control and uninterrupted production.

    Kohdistuu: Manufacturing sites and external suppliers

Kysy Clarifolta: LEO Pharma A/S

Kirjanpito

Harkinnanvaraiset erät
In-licensed intangible assets

Acquired or licensed rights may be capitalized and amortized based on expected product life and recoverability.

Vaikutus: Can materially affect operating profit and balance-sheet asset values

Development costs

Judgment is required on which research and development expenditures are expensed versus capitalized under IFRS.

Vaikutus: Affects reported R&D expense and future amortization

Inventory valuation

Finished goods and active pharmaceutical ingredients can require write-downs if demand or shelf-life assumptions weaken.

Vaikutus: Impacts cost of sales and gross profit

Derivatives and hedging

Foreign exchange and interest-rate instruments can create gains or losses depending on hedge accounting treatment.

Vaikutus: Affects finance income/expense and OCI volatility

Päivitetty: 24.10.2026